Search hospitals > Illinois > Peoria
Illinois CancerCare-Peoria
Claim this profilePeoria, Illinois 61615
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
688 reported clinical trials
9 medical researchers
Summary
Illinois CancerCare-Peoria is a medical facility located in Peoria, Illinois. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Illinois CancerCare-Peoria is involved with conducting 688 clinical trials across 611 conditions. There are 9 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Leonard Klein, and Nguyet A Le-Lindqwister, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
BRAF positive
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Bryan A. FallerCrossroads Cancer Center6 years of reported clinical research
Expert in Skin Cancer
Expert in Cancer
239 reported clinical trials
296 drugs studied
James L. WadeDecatur Memorial Hospital4 years of reported clinical research
Studies Relapse
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Leonard KleinIllinois Cancer Specialists4 years of reported clinical research
Studies Lymphoma
Studies B-Cell Lymphoma
10 reported clinical trials
26 drugs studied
Nguyet A Le-Lindqwister, MDIllinois Cancer Care6 years of reported clinical research
Studies Lymphoma
Studies Hodgkin's Lymphoma
4 reported clinical trials
10 drugs studied
Clinical Trials running at Illinois CancerCare-Peoria
Lung Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Breast cancer
Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Bladder Cancer
Ovarian Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Illinois CancerCare-Peoria?
Illinois CancerCare-Peoria is a medical facility located in Peoria, Illinois. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Illinois CancerCare-Peoria is involved with conducting 688 clinical trials across 611 conditions. There are 9 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Leonard Klein, and Nguyet A Le-Lindqwister, MD.
Where is Illinois CancerCare-Peoria located?
**Illinois CancerCare - Peoria Hospital**
- **Address:** 8940 N Wood Sage Rd, Peoria, IL 61615
- **Hours:**
- Monday to Thursday: 7:30 AM - 5:00 PM
- Friday: 8:00 AM - 5:00 PM
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Peoria Financial Assistance:**
- For financial assistance, contact OSF HealthCare Patient Financial Services at (800) 421-5700 or visit 1420 W. Pioneer Parkway, Peoria, IL 61615.
- Assistance is available for those who qualify, including the uninsured and underinsured. Proof of income and state residency is required.
- Pre-approval for financial assistance is available and typically processed within two weeks, valid for 12 months.
**Insurance Inquiries:**
- For insurance questions, contact Illinois CancerCare-Peoria at (309) 243-3000 or (866) 662-6564, or visit 8940 N Wood Sage Rd, Peoria, IL 61615.
- They address inquiries related to treatment, research, and education in the fight against cancer and blood disorders.
What insurance does Illinois CancerCare-Peoria accept?
Illinois CancerCare-Peoria accepts a range of insurance plans, both commercial and government. Patients with HMO or PPO plans should verify if specific physicians are covered. It's also recommended to check if pre-certification is required with your insurance plan.
What awards or recognition has Illinois CancerCare-Peoria received?
Illinois CancerCare-Peoria, located in Peoria, Illinois, is renowned for its exceptional contribution to clinical research, being named one of the nation's top enrollers by the Alliance for Clinical Trials in Oncology in 2015. The hospital has also earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program, affirming its adherence to the highest standards of quality cancer care. Demonstrating its commitment to advancing cancer treatment, Illinois CancerCare-Peoria has successfully enrolled 201 patients into 30 different NCI-funded clinical trials across more than 15 cancer types.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.